Biotech · Private company
AlloVir
Track this companyFree. Adds AlloVir to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- PosoleucelPhase 3 · Adenovirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Posoleucel (ALVR105)Phase 3 · Adenovirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Posoleucel (ALVR105)Phase 3 · BK Virus InfectionClinicalTrials.gov · fetched Nov 12, 2026
- ALVR106Phase 2 · Respiratory Tract Viral InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Multivirus-specific T cells Dose Level 1Phase 2 · Viral InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Multivirus-specific T cells Dose Level 2Phase 2 · Viral InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Multivirus-specific T cells Dose Level 3Phase 2 · Viral InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Posoleucel (formerly known as ALVR105) cellsPhase 2 · BK Virus NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- Multivirus Specific T cellsInfectionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell TransplantationPHASE3 · TERMINATED · started Apr 26, 2022ClinicalTrials.gov NCT05179057 · fetched Nov 12, 2026
- Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantPHASE2_PHASE3 · TERMINATED · started Mar 24, 2022ClinicalTrials.gov NCT05305040 · fetched Nov 12, 2026
- Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ TransplantPHASE1_PHASE2 · TERMINATED · started Mar 21, 2022ClinicalTrials.gov NCT04933968 · fetched Nov 12, 2026
- Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK ViremiaPHASE2 · COMPLETED · started Mar 22, 2021ClinicalTrials.gov NCT04605484 · fetched Nov 12, 2026
- Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)PHASE3 · TERMINATED · started Mar 18, 2021ClinicalTrials.gov NCT04390113 · fetched Nov 12, 2026
- Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantPHASE2_PHASE3 · COMPLETED · started Jan 15, 2021ClinicalTrials.gov NCT04693637 · fetched Nov 12, 2026
- Anti-SARS Cov-2 T Cell Infusions for COVID 19PHASE1 · TERMINATED · started Nov 4, 2020ClinicalTrials.gov NCT04401410 · fetched Nov 12, 2026
- Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell TransplantNA · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02108522 · fetched Nov 12, 2026
- ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK VirusPHASE1_PHASE2 · COMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01570283 · fetched Nov 12, 2026